Skip to main content
Articles & Publications , Thierry Van Nieuwenhove

Translational Pharmaceutics® Platform Remains a Primary Goal for Quotient Sciences

Thierry Van Nieuwenhove

In this article by 247 BioPharma, Thierry Van Nieuwenhove, the CEO of Quotient Sciences discusses the primary company goals and what steps the Quotient Sciences is taking to meet evolving regulatory requirements.

In addition, Thierry talks about the importance of partnerships and collaborations for the Quotient Sciences growth strategy and what key innovations, or new products will company be showcasing at CPHI Milan this year.

Continue reading the full article or watching the video on 247Bio Pharma.

Latest news from Quotient Sciences

More News
Articles & Publications, Dr. Andy Lewis, AI, Clinical Trials The Future of Pharma: How AI is Transforming the Industry By: Dr. Andrew Lewis
Read More
formulation development, GLP-1, Peptides, Dr. Andy Lewis, Dr. Andrew Parker Video Interview: Dr. Andrew Lewis and Dr. Andrew Parker Speak with Manufacturing Chemist at CPHI Milan
Read More
Get in touch
Humanity can't afford to wait, so neither can we.